AU2001233873B2 - Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity - Google Patents

Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity Download PDF

Info

Publication number
AU2001233873B2
AU2001233873B2 AU2001233873A AU2001233873A AU2001233873B2 AU 2001233873 B2 AU2001233873 B2 AU 2001233873B2 AU 2001233873 A AU2001233873 A AU 2001233873A AU 2001233873 A AU2001233873 A AU 2001233873A AU 2001233873 B2 AU2001233873 B2 AU 2001233873B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
compound
alkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001233873A
Other languages
English (en)
Other versions
AU2001233873A1 (en
Inventor
Dolores Garcia Gravalos
Tatsuo Higa
Junichi Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0003629A external-priority patent/GB0003629D0/en
Priority claimed from GB0021774A external-priority patent/GB0021774D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of AU2001233873A1 publication Critical patent/AU2001233873A1/en
Application granted granted Critical
Publication of AU2001233873B2 publication Critical patent/AU2001233873B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
AU2001233873A 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity Ceased AU2001233873B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0003629A GB0003629D0 (en) 2000-02-16 2000-02-16 Antitumour agent
GB0003629.3 2000-02-16
GB0021774.5 2000-09-05
GB0021774A GB0021774D0 (en) 2000-09-05 2000-09-05 Anti-tumour compound
PCT/GB2001/000655 WO2001060810A1 (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Publications (2)

Publication Number Publication Date
AU2001233873A1 AU2001233873A1 (en) 2001-11-08
AU2001233873B2 true AU2001233873B2 (en) 2006-03-02

Family

ID=26243662

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001233873A Ceased AU2001233873B2 (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
AU3387301A Pending AU3387301A (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3387301A Pending AU3387301A (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Country Status (17)

Country Link
US (1) US6864283B2 (enExample)
EP (1) EP1255746B1 (enExample)
JP (1) JP2003523338A (enExample)
KR (1) KR20020092958A (enExample)
CN (1) CN1318409C (enExample)
AT (1) ATE316524T1 (enExample)
AU (2) AU2001233873B2 (enExample)
BR (1) BR0108448A (enExample)
CA (1) CA2400612C (enExample)
CZ (1) CZ20022791A3 (enExample)
DE (1) DE60116855T2 (enExample)
ES (1) ES2256199T3 (enExample)
IL (1) IL151241A (enExample)
MX (1) MXPA02007995A (enExample)
PL (1) PL357193A1 (enExample)
RU (1) RU2002124591A (enExample)
WO (1) WO2001060810A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
CN102229585A (zh) * 2011-04-26 2011-11-02 中国人民解放军第二军医大学 具有抗肿瘤活性的γ-丁内酯聚酮类化合物
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US6107520A (en) * 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
AU2001233873B2 (en) 2000-02-16 2006-03-02 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Also Published As

Publication number Publication date
EP1255746A1 (en) 2002-11-13
WO2001060810A1 (en) 2001-08-23
US20030092738A1 (en) 2003-05-15
ES2256199T3 (es) 2006-07-16
AU3387301A (en) 2001-08-27
RU2002124591A (ru) 2004-01-10
DE60116855D1 (de) 2006-04-13
CA2400612A1 (en) 2001-08-23
CA2400612C (en) 2010-05-11
CN1423642A (zh) 2003-06-11
US6864283B2 (en) 2005-03-08
KR20020092958A (ko) 2002-12-12
DE60116855T2 (de) 2006-09-14
JP2003523338A (ja) 2003-08-05
BR0108448A (pt) 2003-04-01
MXPA02007995A (es) 2003-05-23
CZ20022791A3 (cs) 2003-02-12
WO2001060810B1 (en) 2001-11-29
EP1255746B1 (en) 2006-01-25
PL357193A1 (en) 2004-07-26
CN1318409C (zh) 2007-05-30
ATE316524T1 (de) 2006-02-15
IL151241A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
US7795457B2 (en) Carbamate compounds
US20090042837A1 (en) Leptomycin compounds
JP4653950B2 (ja) 新規なｅｔ−７４３の抗腫瘍性誘導体
CA2400612C (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
AU2002217266A1 (en) Antitumoral carbazoles
AU2001233873A1 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
EP3720855B1 (en) Imidazopyridine derivatives and the use thereof as medicament
JP2000502351A (ja) 医薬化合物
US6635656B1 (en) Cytotoxic alkaloids halitulin
EP3759108A1 (de) Polyprolin-mimetika des prolin-abgeleiteten moduls-15
EP1286990B1 (en) Stolonoxides
AU2001254938A1 (en) Stolonoxides
WO2019018890A1 (en) NEW SPIROCYCLIC COMPOUNDS
ITMI962497A1 (it) Derivati 2, 3, 4, 7-tetraidropiridoindazolo-(1,4)benzodiazepinici aventi attivita' antitumorale
HK1163674A (en) Indole derivatives as anticancer agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired